Stock TELO TELOMIR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Telomir Pharmaceuticals, Inc.

Equities

TELO

US87975F1049

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
6.05 USD +1.85% Intraday chart for Telomir Pharmaceuticals, Inc. -10.24% -.--%
May. 30 Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 CI
May. 13 Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore Conference
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to NASDAQ Composite Index
Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TELO Stock
  4. News Telomir Pharmaceuticals, Inc.
  5. Other languages